Before revision: Tissue/cell-type Enriched miRNA Use of the MRE References Liver miR-122 Prevent liver toxicity, hepatotoxicity Muscle miR-133, miR-206 Prevent muscle inflammation, myositis Pancreas miR-148a Promote pancreatic tumor targeting Prostate miR-143, miR-145 Promote prostate tumor targeting Neuron miR-124 Promote astrocyte targeting To enhance the efficacy, therapeutic transgenes are integrated into oncolytic adenovirusstimulation of immune response Immunostimulatory genes such as type I interferons (IFNs) , tumor necrosis factor alpha (TNFα), and interleukin 12 (IL-12) have been added to oncolytic adenovirus to trigger immune activation within the tumor microenvironment.
After revision: ===Arming with transgenes===Tissue/cell-type Enriched miRNA Use of the MRE References Liver miR-122 Prevent liver toxicity, hepatotoxicity Muscle miR-133, miR-206 Prevent muscle inflammation, myositis Pancreas miR-148a Promote pancreatic tumor targeting Prostate miR-143, miR-145 Promote prostate tumor targeting Neuron miR-124 Promote astrocyte targeting To enhance the efficacy, therapeutic transgenes are integrated into oncolytic adenovirusstimulation of immune response Immunostimulatory genes such as type I interferons (IFNs) , tumor necrosis factor alpha (TNFα), and interleukin 12 (IL-12) have been added to oncolytic adenovirus to trigger immune activation within the tumor microenvironment.